Antiarrhythmics or Ablation for Ventricular Tachycardia 2
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
A multicenter, randomized clinical trial to assess whether catheter ablation or
antiarrhythmic drug therapy provides the most effective control of important clinical
outcomes for patients with prior myocardial infarction and sustained monomorphic ventricular
tachycardia (VT).
Phase:
Phase 4
Details
Lead Sponsor:
John Sapp
Collaborators:
Abbott Abbott Medical Devices Biosense Webster, Inc. Canadian Institutes of Health Research (CIHR) Cardiac Arrhythmia Network of Canada Heart and Stroke Foundation of Canada Nova Scotia Health Authority Ottawa Heart Institute Research Corporation St. Jude Medical